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ISOLATION AND CHARACTERIZATION OF A NOVEL BONE FORMING AGENT
(CDROSTEOID-II) FROM NATURAL SOURCE
K. Sharan1, J. Siddiqui1, G. Swarnkar1, P. Rawat2, R. Maurya2, S. Sanyal3,
N. Chattopadhyay1. 1Central Drug Research Institute, Endocrinology,
Lucknow, India; 2Central Drug Research Institute, Medicinal and Process
Chemistry, Lucknow, India; 3Central Drug Research Institute, Drug Target
Discovery and Development, Lucknow, India
Objectives: To evaluate osteogenic property of a molecule (CDROsteoid-II)
isolated from an Indian terrestrial plant and its mode of action.
Methods: Rat calvarial osteoblasts and Cos-7 cells were used for all in
vitro experiments. In vivo effect of CDROsteoid-II on bone were studied in
female Sprague Dawley (weaning) rats and adult ovariectomized (OVx) rats.
Results: CDROsteoid-II at 10-7M stimulated osteoblast proliferation,
survival, differentiation and mineralization. CDROsteoid-II had no effect
on osteoclast differentiation. CDROsteoid-II signals via aryl hydrocarbon
receptor (AHR) in osteoblasts. When CDROsteoid-II was given to weaning
female Sprague Dawley rats (5.0 mg-1 kg-1 day-1) orally for 30 consecutive
days, mineral apposition rate, bone formation rate and mineralization
surface, assessed by tetracycline - calcein labeling, were significantly higher
than the vehicle treated group. Next, CDROsteoid-II was given to adult OVx
Sprague Dawley rats (5.0 mg-1 kg-1 day-1) for 3 months and compared with
vehicle treated OVx- or sham surgery rats. OVx + vehicle group had reduced
BMD and bone biomechanical strength along with microarchitectural dete-
rioration compared with sham + vehicle group; all these parameters in OVx
+ CDROsteoid-II group were comparable with sham + vehicle group. Serum
osteocalcin and urinary CTx levels were higher in OVx + vehicle than sham
+ vehicle group and these levels in OVx + CDROsteoid-II group were compa-
rable to sham + vehicle group. CDROsteoid-II had no uterine estrogenicity.
Conclusions: CDROsteoid-II is a novel AHR modulator exerting osteogenic
action, thus having therapeutic potential in menopausal osteoporosis.
Keywords: Aryl hydrocarbon receptor, osteogenic, phytochemical,
menopausal osteoporosis, bone anabolic, peak bone mass.
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POSTMENOPAUSAL EVALUATION AND RISK-REDUCTIONWITH
LASOFOXIFENE (THE PEARL TRIAL): GYNAECOLOGICAL OUTCOMES AT
FIVE-YEARS
S. Goldstein1, U. Sriram2, P. Neven3, T. Colgan4, C. Runowicz5, D. Krpan6,
Z. Giljevic7, S. Cumming8, J. Proulx9, M. Johnson9, D. Thompson9,
J. Thompson10. 1New York University School of Medicine, Obstetrics and
Gynaecology, New York, United States; 2Associates in Clinical Endocrinology,
Education and Research, Chennai, India; 3UZ Leuven, Gyn Oncol, Leuven,
Belgium; 4Mount Sinai Hospital, Toronto, Canada; 5University of Connecticut
Cancer Center, Farmington, United States; 6Poliklinika Lozo, Zadar, Croatia;
7Klinicki Bolnicki Centar, Zagreb, Croatia; 8University of California, San
Francisco, United States; 9Pfizer Global Research and Development, New
London, CT, United States; 10Pfizer Global Research and Development, New
London, United States
Objectives: To establish the gynecological safety profile of 5-years treat-
ment with lasofoxifene versus placebo in postmenopausal women at risk
for osteoporosis over five years.
Methods: In this randomized trial, 8556 women aged 59 to 80 years
with femoral neck or spine bone mineral density T-scores ≤-2.5 received
lasofoxifene 0.25 mg/d, 0.5 mg/d, or placebo for five years.
Results: Endometrial cancer was confirmed for seven subjects (two subjects
in each lasofoxifene group and three placebo subjects). Endometrial hyper-
plasia was confirmed for five subjects: three subjects in the lasofoxifene
0.25 mg/d group, two subjects in the lasofoxifene 0.5 mg/d group, and
no subjects in the placebo group. Vaginal bleeding occurred in 2.2% (p
= 0.012), 2.6% (p = 0.001), and 1.3% of patients treated with 0.25 mg/d
lasofoxifene, 0.5 mg/d lasofoxifene, and placebo, respectively; the excess
in vaginal bleeding observed with lasofoxifene treatment were attributed
to the benign endometrial effects of lasofoxifene. Lasofoxifene treatment
was associated with a small increase in endometrial thickness compared
to placebo (LS mean change -0.72 mm, 1.19 mm [p=0.001], and 1.43
mm [p<0.001] for placebo, 0.25 mg/d, and 0.5 mg/d lasofoxifene). The
number of subjects requiring surgery for pelvic organ prolapse or urinary
incontinence was similar between subjects treated with placebo and 0.5
mg/d lasofoxifene (1.2% vs 1.6%, p=0.224).
Conclusions: These findings indicated that lasofoxifene treatment over five
years did not increase the risk for endometrial cancer or hyperplasia in
postmenopausal women.
Keywords: SERM, lasofoxifene, osteoporosis, endometrial cancer or hyper-
plasia.
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EQUOL BUT NOT GENISTEIN IMPROVES FRACTURE HEALING IN SEVERE
EXPERIMENTAL OSTEOPOROTIC BONE
L. Kolios, S. Sehmisch, F. Daub, T. Rack, M. Tezval, K.M. Stuermer,
E.K. Stuermer. University of Goettingen, Department of Trauma and
Reconstructive Surgery, Göttingen, Germany
Objectives: Healing of predominantly metaphyseal fractures in post-
menopausal osteoporosis is delayed and comparatively poor. HRT could
improve fracture healing, but, because of potential side effects, natural
alternatives are appealing. The study examined if the soy metabolites
equol and genistein, in comparison to 17-β-estradiol, improve metaphyseal
fracture healing in postmenopausal osteoporotic bone.
Methods: Forty-eight 12-week-old rats developed severe osteoporosis
eight weeks after ovariectomy. After a metaphyseal tibial osteotomy and
standardized stable internal fixation, changes in callus morphology were
evaluated biomechanically, qualitatively and quantitatively (in histological
sections and microradiographies) in ovariectomized rats (C) and under stan-
dardized 17-β-estradiol- (E), equol- (EQ) and genistein (G)-supplemented
diets over a period of five weeks.
Results: Estrogen and equol improve the stiffness of callus formation sig-
nificantly in postmenopausal osteoporotic bone (S[N/mm]C: 121.4±47.08,
E: 147.9±39.38, EQ: 167.8±59.9). The effects of estrogen are evident
in trabecular bone (N.Nd [abs] of E: 6.47±7.68, EQ: 4.25±3.96). But
in terms of the whole body, equol induces a less adverse reaction
than estrogen (bodyweight of C: 342.2±19.91g, E: 280.25±12.05g EQ:
308.75±24.28g). Genistein as an osteoclast inhibitor influences callus stiff-
ness (G: 144.5±61.52 N/mm) and negatively impacts trabecular structure
(N.Nd [abs] of G: 0.59±1.01) in severely osteoporotic bone.
Conclusions: Estrogen and equol improve fracture healing in post-
menopausal osteoporotic bone, and the extent of callus formation plays
only a minor role. Genistein negatively influences fracture healing. The
metaphyseal osteotomy model in ovariectomized rats allows researchers
to accurately study the therapeutic effects of antiosteoporotic substances.
Keywords: Fracture healing - osteoporosis - estrogen - phytoestrogen -
equol - genistein.
Free Communications: Women’s Health
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PSYCHOBIOLOGICAL PREDICTORS OF EXERCISE BEHAVIOUR IN
POSTMENOPAUSAL WOMEN
F. Barnett. James Cook University, Townsville, Australia
Objectives: Weight gain and obesity-related diseases are associated with
the postmenopausal period. Moderate intensity exercise may be protec-
tive through attenuation of weight gain, however, many postmenopausal
women do not engage in regular exercise. This study investigated the
exercise behaviour of postmenopausal women in regional Queensland
to determine whether differences existed for personal, physiological and
psychological variables and if so, which of these variables may predict
future exercise behaviour.
Methods: Participants were postmenopausal women (N=101) resident in
North Queensland. A self-report questionnaire, the Self-efficacy for Exercise
Scale and the Health Belief Model Scale were completed.
Anthropometric and physiological measures were obtained. Participants
also completed a 20 minute moderate intensity exercise bout on a cycle
ergometer; measures of affect were obtained using the Subjective Exercise
Experience Scale. Participants were then categorised as exercisers (n=53)
or non-exercisers (n=48).
Results: Compared to the exercisers, the non-exercisers had a lower level of
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education (U=971.5, p=0.03), cardio respiratory fitness (F1,99=21.57, p=0.00)
and exercise self-efficacy (F1,99=39.56, p=0.00) and higher resting diastolic
blood pressure (F1,99=7.57, p=0.01) and BMI (F1,99=33.63, p=0.00).
The barrier items of perceived lack of time, difficulty getting to an
exercise location and the weather provided the greatest discrimination
between exercisers and non-exercisers. However, the acute exercise bout
produced higher positive well-being postexercise compared to pre and
during exercise for both groups.
Conclusions: Identification of the differences in exercise behaviour be-
tween exercisers and non-exercisers may provide information for future
health promotion policy directions for this population and allow for the
formulation of guidelines for exercise professionals.
Keywords: Postmenopausal women, exercise behaviour.
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EVALUATION OF THE HYPERLIPIDEMIA AND HYPERGLYCEMIA IN
PROGESTERONE ONLY PILL (POP) USERS
M. Kashanian, M. Fekrat. Iran University of Medical Sciences, Obstetrics and
Gynecology, Tehran, Iran, Islamic Republic of
Objectives: Evaluation of the hyper lipidemia and hyperglycemia in the
progesterone only pill (POP) users.
Methods: A semi-experimental study was performed on 170 women, who
were 20-45 years old and used lynesterenol (POP), as a contraceptive.
Fasting blood sugar (FBS), serum cholesterol, serum triglyceride (TG), serum
HDL-Cholesterol, serum LDL-Cholesterol, were measured at the beginning
of lynesterenol use and again 6 months after its use.
Results: FBS was 65.3±5.2 mg/dl and 88±6.1mg/dl before and after the
treatment respectively, which showed a statistically significant difference,
(p<0.001, pair t test), but the values after treatment, were in the normal
range. Cholesterol was 161.5±20.2 mg/dl and 169±10.5 mg/dl before and
after the treatment respectively, which showed a statistically significant
difference (p<0.001, pair t test), and again values after treatment were in
the normal range. TG was 73.7±8.7 and 76.4±7.1 mg/dl before and after the
drug use, respectively, without a statistically significant difference. LDL-C
was 108±10.2 and 111±8.5 mg/dl, and HDL-C was 41.4±3.5 and 39.1±4.2
mg/dl before and after the treatment respectively, without a statistically
significant difference.
Conclusions: Regarding to the small effects of POPs on lipid profile and
blood sugar, it can be offered as an effective method for contraception in
patients who are at risk for cardiovascular disease and also diabetese and
in women who can not use combined pills, and also in women older than
40 years old, because in this group of patients, unwanted estrogen effects
are dangerous.
Keywords: Contraception, perimenopause, progesterone only pill (POP).
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SMART-2: A PHASE III STUDY OF THE EFFICACY AND SAFETY OF
BAZEDOXIFENE/CONJUGATED ESTROGENS (BZA/CE) FOR TREATMENT OF
MENOPAUSAL VASOMOTOR SYMPTOMS
J. Pinkerton1, W. Utian2, G. Constantine3, S. Olivier3, J. Pickar3. 1University
of Virginia, Charlottesville, United States; 2Case Western Reserve University,
Cleveland, United States; 3Wyeth Research, Collegeville, United States
Objective: Bazedoxifene (BZA) partnered with conjugated estrogens (CE) is
a novel tissue selective estrogen complex (TSEC). In a prior 2-year, double-
blind trial, BZA 20 mg/CE 0.45 or 0.625 mg was shown to significantly
increase bone mineral density and reduce the frequency and severity of
hot flushes (HFs) compared with placebo without endometrial stimulation
in postmenopausal women. The SMART-2 (Selective estrogens, Menopause
And Response to Therapy-2) trial evaluated the efficacy and safety of
BZA/CE versus placebo for treatment of moderate-to-severe vasomotor
symptoms.
Methods: This 12-week trial randomized 332 postmenopausal women with
≥7 moderate-to-severe HFs daily (or ≥50 per week) to receive BZA 20
mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, or placebo. Subjects recorded the
number and severity of HFs daily. Transvaginal ultrasound was performed
at baseline and 12 weeks.
Results: BZA 20 mg/CE 0.45 and 0.625 mg showed significantly greater
reductions in number of moderate-to-severe HFs at weeks 4 and 12 versus
placebo (P<0.001), achieving 74% and 80% reductions from baseline at
week 12, respectively. Statistically significant improvements over placebo
were observed in daily number of moderate-to-severe HFs with BZA 20
mg/CE 0.45 mg from week 3 onward and with BZA 20 mg/CE 0.625 mg
from week 2 onward. There were no differences in incidence of adverse
events or changes in endometrial thickness among groups.
Conclusion: BZA/CE, the first TSEC, effectively and safely reduced the
number and severity of HFs in this study of symptomatic postmenopausal
women with no evidence of endometrial stimulation.
Keywords: TSEC, menopause, vasomotor symptoms.
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SMART-3: EFFECTS OF BAZEDOXIFENE/CONJUGATED ESTROGENS
(BZA/CE) ON VULVAR/VAGINAL ATROPHY (VVA) AND SEXUAL FUNCTION
IN POSTMENOPAUSALWOMEN
R. Kagan1, M. Gass2, R. Williams3, S. Olivier4, J. Pickar4. 1Foundation for
Osteoporosis Research and Education, Oakland, United States; 2University of
Cincinnati College of Medicine, Cincinnati, United States; 3University of Florida
College of Medicine, Gainesville, United States; 4Wyeth Research, Collegeville,
United States
Objective: The first tissue selective estrogen complex (TSEC), bazedoxifene
(BZA) with conjugated estrogens (CE), was shown to prevent bone loss with
favorable endometrial, tolerability, and safety profiles in postmenopausal
women in the 2-year SMART-1 (Selective estrogens, Menopause And
Response to Therapy-1) trial. The SMART-3 trial assessed the efficacy and
safety of BZA/CE versus placebo for treatment of vulvar/vaginal atrophy
(VVA) and impact on sexual function.
Methods: In this 12-week double-blind phase 3 study, 652 postmenopausal
women aged 40-65 years with moderate-to-severe VVA, vaginal pH >5.0,
and ≤5% superficial cells were randomized to receive BZA 20 mg/CE 0.45
mg, BZA 20mg/CE 0.625 mg, BZA 20mg, or placebo daily. Primary endpoints
were percentage of vaginal superficial and parabasal cells, vaginal pH, and
severity of most bothersome VVA symptom at week 12; secondary end-
points included Arizona Sexual Experiences Scale (ASEX) and Menopause-
Specific Quality of Life (MENQOL) total and sexual function scores.
Results: At week 12, BZA 20 mg/CE 0.45 and 0.625 mg significantly in-
creased the percentage of superficial cells and decreased the percentage of
parabasal cells compared with placebo (P<0.001 and P≤0.01, respectively).
Vaginal pH and most bothersome symptom scores were significantly im-
proved with BZA 20 mg/CE 0.625 mg versus placebo (P<0.001 and P<0.05,
respectively). ASEX lubrication and MENQOL total and sexual function
scores were significantly improved over placebo in both BZA/CE groups
(P<0.05 for all).
Conclusion: TSECs containing BZA/CE improved biologic markers of VVA
and sexual function in postmenopausal women.
Keywords: TSEC, menopause, VVA, sexual functionl.
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EUROPEAN UNION STANDARDS IN MENOPAUSE SERVICE: A ROLE FOR
EMAS
S. Sharma, C.A. Pop, J. Pitkin. Northwick Park & St Mark’s Hospitals,
Menopause Clinical and Research Unit, Harrow, United Kingdom
Objectives: To explore a possible role for the European Menopause and
andropause society (EMAS) for standards setting in menopause which,
could be tailored to individual European Union countries needs.
Methods: An e-mail questionnaire survey of menopause specialists from
twenty-seven European Union countries and Switzerland was undertaken
in September to November 2008.
Table 1. National gynaecological society recommendation
Recommendations
Areas covered Yes %
Standards for menopause 75%
Hormone replacement therapy recommendations 50%
Non-hormonal therapy 50%
Bone density scans for osteoporosis 50%
Breast screening 75%
Multi-disciplinary approach 75%
Gynaecology standards 75%
